You are here: Industry Insights > WP1122

News List

Moleculin Selects IQVIA Biotech to Advance COVID Treatment contractpharma
April 08, 2021
IQVIA to manage the company's effort to begin potential clinical trials of WP1122 for the treatment of COVID-19.
In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus americanpharmaceuticalreview
July 28, 2020
Moleculin Biotech announced a second round of independent laboratory testing has confirmed the antiviral activity of WP1122 against coronavirus.
Moleculin Enters Agreement with Sterling Pharma contractpharma
July 16, 2020
Will produce WP1122 for potential treatment of COVID-19.
Moleculin Provides Update on Coronavirus Drug Development americanpharmaceuticalreview
June 03, 2020
Moleculin Biotech announced the US Food and Drug Administration (FDA) has granted the Company's request for a Pre-IND Meeting to provide guidance regarding the Company's plan to study its drug candidate, WP1122 ...
WPD Partners with CNS on Drug Development for Coronavirus, Other Antiviral Indication americanpharmaceuticalreview
March 26, 2020
WPD Pharmaceuticals has entered into a development agreement with CNS Pharmaceuticals for the development of several preclinical drug candidates including WP1122.
CNS, WPD Pharma to Develop Coronavirus Candidates contractpharma
March 24, 2020
To develop several preclinical drug candidates including WP1122, which is being tested on a range of viruses including coronavirus.
Moleculin, UTMB partner to study WP1122 for coronavirus pharmaceutical-technology
March 19, 2020
Moleculin Biotech has partnered with the University of Texas Medical Branch at Galveston (UTMB) to test its molecular inhibitors, including WP1122, to treat different viruses ...